Barinthus Biotherapeutics plc (BRNS)
| Market Cap | 30.49M -34.3% |
| Revenue (ttm) | n/a |
| Net Income | -41.77M |
| EPS | -1.02 |
| Shares Out | 40.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,317 |
| Open | 0.7310 |
| Previous Close | 0.7312 |
| Day's Range | 0.7000 - 0.7495 |
| 52-Week Range | 0.5120 - 1.8300 |
| Beta | -0.39 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+703.97%) |
| Earnings Date | Aug 6, 2026 |
About BRNS
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for BRNS stock is "Strong Buy." The 12-month stock price target is $6.0, which is an increase of 703.97% from the latest price.
News
Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics
Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cea...
Barinthus Biotherapeutics price target lowered to $6 from $7 at Alliance Global
Alliance Global lowered the firm’s price target on Barinthus Biotherapeutics (BRNS) to $6 from $7 and keeps a Buy rating on the shares following the company’s Q2 update. The firm’s…
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients wi...
Barinthus Biotherapeutics Quarterly report: Q2 2026
Barinthus Biotherapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Barinthus Biotherapeutics Earnings release: Q2 2026
Barinthus Biotherapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Barinthus Biotherapeutics Proxy statement: Proxy filing
Barinthus Biotherapeutics filed a proxy statement on June 10, 2026, providing details for shareholder voting and corporate governance matters.
Barinthus Biotherapeutics Proxy statement: Proxy filing
Barinthus Biotherapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended March ...
Barinthus Biotherapeutics Earnings release: Q1 2026
Barinthus Biotherapeutics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Barinthus Biotherapeutics Quarterly report: Q1 2026
Barinthus Biotherapeutics has published its Q1 2026 quarterly earnings report on April 30, 2026.
Barinthus Biotherapeutics Slides: Corporate presentation
Barinthus Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 30, 2026.
Barinthus Biotherapeutics reports FY25 EPS ($1.64) vs ($1.55) last year
“As we move into 2026, we are excited by the proposed combination of Barinthus Bio and Clywedog, which positions us for multiple near-term catalysts emerging from our differentiated and complimentary…
Barinthus Biotherapeutics Earnings release: Q4 2025
Barinthus Biotherapeutics released its Q4 2025 earnings on March 13, 2026, summarizing the period's financial results.
Barinthus Biotherapeutics Annual report: Q4 2025
Barinthus Biotherapeutics has published its Q4 2025 annual report on March 13, 2026.
Barinthus Biotherapeutics Slides: Corporate presentation
Barinthus Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000
Barinthus Biotherapeutics (BRNS) announced an update on its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. In the single ascending dose, SAD, portion of the trial, VTP-1000…
Barinthus Biotherapeutics price target raised to $4 from $3 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Barinthus Biotherapeutics (BRNS) to $4 from $3 and keeps a Buy rating on the shares following the Q3 report. Published first on…
Barinthus Biotherapeutics reports Q3 EPS (36c) vs (21c) last year
“The proposed combination of Barinthus Bio and Clywedog represents an important step toward building a stronger, more resilient company, with several expected near-term catalysts.” said Bill Enright, ...
Barinthus Biotherapeutics Earnings release: Q3 2025
Barinthus Biotherapeutics released its Q3 2025 earnings on November 7, 2025, summarizing the period's financial results.
Barinthus Biotherapeutics Quarterly report: Q3 2025
Barinthus Biotherapeutics has published its Q3 2025 quarterly earnings report on November 7, 2025.
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
SAN DIEGO , Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical phar...
BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Bar...
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- GERMANTOWN, MD and ALTRINCHAM, UK — September 30, 2025 — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), an immuno...
Barinthus Bio, Clywedog enter definitive merger agreement
Barinthus Biotherapeutics (BRNS) and Clywedog Therapeutics entered into a definitive merger agreement to combine in an all-stock transaction. The newly combined company will advance a novel portfolio ...
Barinthus Biotherapeutics Earnings release: Q2 2025
Barinthus Biotherapeutics released its Q2 2025 earnings on August 7, 2025, summarizing the period's financial results.